Skip to main content
SpringerLink
Log in

Prescribing Trends and Pharmacoeconomic Considerations in the Treatment of Arrhythmias

Focus on Atrial Fibrillation and Flutter

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Considerable progress has been made regarding the trealment of atrial fibri llation and atrial flutter. However, controversies s lill exist with respect to the therapy o f choice for ventricular rate control, requirements for long tenn preventive therapy, and the place of surgical and ablatio n alternatives. Surrounding these controversies also lies a paucity of phannacoeconomic studies, which limits delineation of the most cost–effective therapy for patients with at rial fibrillation and atrial flutter. This article reviews prescribing trends in the US for antiarrhythmic agents, and the available phannacoeconomic studies that have specifi call y addressed the treatment of atrial fibrillation and atrial flutter.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hine LK, Gross TP, Kennedy D. Outpatient antiarrhythmic drug use from 1970 through 1986. Arch Intern Med 1989; 149: 1724–7

    Article  Google Scholar 

  2. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients recieving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–8

    Article  PubMed  CAS  Google Scholar 

  3. Morganroth J, Bigger JT, Anderson JL. TReament of ventricular arrhythmias by United States cardiologists: a survey before the Cardiac Arrhythmia Suppression Trial results were available. Am J Cardiol 1990; 65: 40–48

    Article  PubMed  CAS  Google Scholar 

  4. Vlay SC. How the university cardiologist treats ventricular premature beats: a nationwide survey of 65 universty medical centers. Am Heart J 1985; 110: 904–12

    Article  PubMed  CAS  Google Scholar 

  5. Wenger NK, Hellerstein HK, Blackburn H, et al. Physician practice in management of patients with uncomplicated myocardial infarction: changes in the past decade. Circulation 1982; 65: 421–1

    Article  PubMed  CAS  Google Scholar 

  6. Morganroth J, Goin JE. Quinidine–related mortality in the short–to–medium term treatment of ventricular arrhythmias; a metal analysis. Circulation; 1991; 84; 1977–83

    Article  PubMed  CAS  Google Scholar 

  7. Stanek EJ, Schoen M, Bauman JL. Issues in the treatment of ventricular ectopy: past present and future controversy. J Pharm Pract 1990: III: 283–94

    Article  Google Scholar 

  8. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine thcerapy for maintenance of sinus rhythm after cardioversion: a metal analysis of randomized control trials. Circulation 1990; 82: 1106–16

    Article  PubMed  CAS  Google Scholar 

  9. F1aker GC, Blackshear JL, McBride R, et al. Antiarmythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527–32

    Article  PubMed  CAS  Google Scholar 

  10. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation study: final results. Circulation 1991; 84: 527–39

    Google Scholar 

  11. Jackman WM, Wang X, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff–Parkinson–White–syndrome) by radiofrequency current. N Engl J Med 1991; 324: 1605–11

    Article  PubMed  CAS  Google Scholar 

  12. Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequecy catheter ablation of slow pathway conduction. N Engl J Med 1992; 327: 313–8

    Article  PubMed  CAS  Google Scholar 

  13. Cox JL, Schuessler RB, D’Agostino HJ, et al. The surgical treatment of atrial fIbrillation III. Development of a difinitive surgical procedure. J Thorac Cardiovasc Surg 1991; 101:569–83

    PubMed  CAS  Google Scholar 

  14. Gosselink ATM, Crijns HJGM, Van Gelder IC, et al. Low–dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289–93

    Article  PubMed  CAS  Google Scholar 

  15. Barbarash RA, Bauman JL, Lukazeski AA, et al. Verapamil infusions in the treatment of atrial tachycardias. Crit Care Med 1986; 14: 886–8

    Article  PubMed  CAS  Google Scholar 

  16. Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo controlled trial of continuous intravenous diltiazem infusion for 24 hourheart rate control during atrial fibrillation and atrial flutter. J Am Coll Cardiol 1989; 18: 891–7

    Article  Google Scholar 

  17. Salerno DM, Dias CV, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for the treatment of atrial fibrillation and atrial flutter. Am J Cardiol 1989; 63: 1046–51

    Article  PubMed  CAS  Google Scholar 

  18. Seto TB, Taira DA, Tsevat J, et al. Cost–effectiveness of early cardioversion guided by transesophageal echocardiographyfor hospitalized patients with atrial fibrillation [abstract]. J Am Coll Cardiol 1995; 25 (2): 202A

    Article  Google Scholar 

  19. Stroke Prevention in Atrial Fibrillation Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990; 322: 863–8

    Google Scholar 

  20. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrialfibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687–91

    Google Scholar 

  21. Petersen P, Boysen G, Gootfredsen J. et al. Placebo–controlled,randomized trial of warfarin and aspirin for prevention of thromboembolic complcations in chronic atrial fibrillation:the Copenhagen AFASAK study. Lancet 1989; 1: 175–9

    Article  PubMed  CAS  Google Scholar 

  22. Podrid PJ, Arnold RJG, Kaniecki DJ. Pharmacoeconomics considerations in antiarrhythmic therapy. PharmacoEconomics 1992; 2: 456–67

    Article  PubMed  CAS  Google Scholar 

  23. Roberts SA, Diaz C, Nolan PE, et al. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardioll 1993; 72: 567–73

    Article  CAS  Google Scholar 

  24. Talbert RL, Stewart A. A pharmaeconomic analysis of the Stroke Prevention in Atrial Fibrillation (SPAF) trial [abstract]. Pharmacotherapy 1993; 13: 683

    Google Scholar 

  25. Gustafsson C, Asplund K, BriltOn M, et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457–60

    Article  PubMed  CAS  Google Scholar 

  26. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sections of Cardiovascular Pharmacotherapy and Cardiology, Colleges of Pharmacy and Medicine, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois, 60612-7230, USA

    Bradley G. Phillips &  Jerry L. Bauman

Authors
  1. Bradley G. Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerry L. Bauman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Phillips, B.G., Bauman, J.L. Prescribing Trends and Pharmacoeconomic Considerations in the Treatment of Arrhythmias. Pharmacoeconomics 7, 521–533 (1995). https://doi.org/10.2165/00019053-199507060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199507060-00006

Keywords

Search

Navigation